To summarize the current progress in molecular innate immune regulation with a focus on TLRs in the development of vaccines and therapeutic strategies for allergic rhinitis, emphasizing the significance of TLRs.
Key Findings:
Allergic rhinitis (AR) is an IgE-dependent, Th2 cell-mediated disorder that significantly impairs quality of life.
Conventional treatments for AR provide symptomatic relief but do not modify underlying immunopathology.
Allergen immunotherapy (AIT) induces immune tolerance but typically requires prolonged treatment and may have suboptimal responses.
Toll-like receptors (TLRs) are critical in orchestrating immune responses and are being investigated as therapeutic targets.
TLR agonists can enhance immunogenicity and skew immune responses towards Th1 or regulatory phenotypes.
Interpretation:
Limitations:
The review focuses on literature published until 2023, which may not include the most current research.
The efficacy and safety of TLR agonists in clinical settings require further validation through ongoing and future clinical trials.
Conclusion:
The integration of basic immunological mechanisms, preclinical evidence, and clinical advances highlights the role of TLR agonists in developing more effective and personalized approaches for AR management.
